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Background: A subset of lung adenocarcinomas harboring an EML4-ALK fusion gene resulting in dominant
oncogenic activity has emerged as a target for specific therapy. EML4-ALK fusion confers a characteristic histology
and is detected more frequently in never or light smokers and younger patients.
Methods: To gain insights into etiology and carcinogenic mechanisms we conducted analyses to compare
allelotypes of 35 ALK fusion-positive and 95 -negative tumours using single nucleotide polymorphism (SNP) arrays
and especially designed software which enabled precise global genomic profiling.
Results: Overall aberration numbers (gains + losses) of chromosomal alterations were 8.42 and 9.56 in tumours
with and without ALK fusion, respectively, the difference not being statistically significant, although patterns of gain
and loss were distinct. Interestingly, among selected genomic regions, oncogene-related examples such as 1p34.3
(MYCL1), 7q11.2(EGFR), 7p21.1, 8q24.21(MYC), 16p13.3, 17q12(ERBB2) and 17q25.1 showed significantly less gain. Also,
changes in tumour suppressor gene-related regions, such as 9p21.3 (CDKN2A) 9p23-24.1 (PTPRD), 13q14.2 (RB1),
were significantly fewer in tumours with ALK fusion.
Conclusion: Global genomic comparison with SNP arrays showed tumours with ALK fusion to have fewer
alterations in oncogenes and suppressor genes despite a similar overall aberration frequency, suggesting very
strong oncogenic potency of ALK activation by gene fusion.
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The adenocarcinoma is the most common form of lung
cancer worldwide, different subsets having specific genetic
backgrounds of great importance for molecular-targeted
therapy. For example, somatic mutations of the epidermal
growth factor receptor (EGFR) are especially prevalent in
adenocarcinomas among never smokers, females, and
those with Asian ethnicity [1]. On the other hand, KRAS
mutations are associated with the smoking habit [2] and
the two tend to be mutually exclusive. Recently, Soda et al.
found a novel fusion gene, EML4-ALK, arising from an* Correspondence: ishikawa@jfcr.or.jp
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reproduction in any medium, provided the orinversion on the short arm of chromosome 2 in non-small
cell lung carcinomas [3]. ALK fusion is a unique example
of tyrosine kinase activation by structural chromosome re-
arrangement [4].
EML4-ALK fusion is a powerful driving molecular event
by itself. The chimeric protein permits ligand-independent
dimerization and constitutive activation of ALK, resulting
in dominant oncogenic activity. Multiple fusion variants of
EML4-ALK and notable clinicopathological characteristics
of fusion positive tumours have been revealed [5-9]. Since
the tyrosine kinase is involved and activated by gene fu-
sion, this type of malignancy has emerged as a target for
anti-tyrosine kinase therapy [4,10-12].
We have revealed that ALK fusion-positive tumours
constituted a particular subset in lung adenocarcinomas inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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well as molecular changes [7,8]. It is of great interest to
assess global genomic alterations to provide deep insight
into their genesis, especially considering these tumours
arise in non- or light smokers. Single nucleotide poly-
morphism (SNP) microarray analysis enables precise high-
throughput detection of genomic copy number alterations,
gains and losses in the genome contributing to carcino-
genesis [13] with gene expression varying consistently with
DNA copy number changes [14,15]. We therefore con-
ducted of the present genomic profiling of lung adenocar-
cinomas with and without ALK fusion.
Methods
Patient population and specimens
A series of 130 cases of lung adenocarcinomas, 35 with
EML4-ALK or KIF5B-ALK fusion and 95 cases without,
were enrolled in this study. From 1998 to 2008, 1,086 pri-
mary lung adenocarcinomas were surgically resected at
Thoracic Surgery Division, the Cancer Institute Hospital,
Japanese Foundation for Cancer Research (JFCR), Tokyo.
All cases were screened as to ALK expression by immuno-
histochemistry using the iAEP method [6] and for positive
cases subsequent RT-PCR and FISH analysis were
performed, as previously described [5,6,16]. Among them,
sufficient amounts and quality of fresh tumour material
were available for 35 cases. Fusion gene variants are listed
in Addtional file 1: Table S1. V3 constituted the largest
proportion, 31% (11/35), having a breakpoint at exon 20
of EML4. A rare variant, KIF5B-ALK fusion, was detected
in two cases. There was no correlation with fusion variant
and pathological subtypes (data not shown). The 95 cases
without ALK fusion were randomly selected from 730
surgically resected adenocarcinomas from 1995 to 2003 at
the same hospital. Tissue specimens were snap-frozen in
liquid nitrogen, typically within 20 minutes after resection,
and stored at −80°C until use. Genomic DNA was
extracted by standard proteinase K digestion and the
phenol-chloroform method. To confirm if specimens used
for analysis in this study contained a significant amount of
tumour cells, typically 50% or more, a neighboring surface
was examined histologically with frozen sections. This
study was approved by the institutional review board of
the JFCR.
Mutation analysis of EGFR, KRAS and TP53
For EGFR mutation analysis, exons 18 to 21 were ampli-
fied by PCR with specific oligo-primers. For point muta-
tions in exon 18, PCR products were directly sequenced.
Fragment analysis was performed for exons 19 and 20
deletions and insertion mutations. The presence of one
point mutation in exon 21 was detected by genotyping
analysis. To examine TP53 mutations, direct sequencing
from exons 5 to 10 was carried out. For KRAS mutationanalysis, codons 12, 13 and 61 were examined by direct
sequencing. Primers and detailed procedures were as
described previously [17].
Histological diagnosis and clinical staging
Histological diagnosis was made on the basis of World
Health Organization (WHO) classification [18] by expe-
rienced pathologists (N.M. and Y.I.). Pathological staging
was based on the AJCC/UICC staging manual of lung
cancer [19]. Differentiation grading of adenocarcinoma
was determined essentially according to the Japan Lung
Cancer Society criteria as illustrated previously [20].
Briefly, well-differentiated (w/d) tumors are composed
chiefly of glands lined by, or of papilla covered by, one-
layered tumor cells. Also, Adenocarcinoma in situ (AIS) is
included in this category. Moderately differentiated (m/d)
lesions comprise glands showing a cribriform pattern,
fused with one another, or glands lined by, or papillae
covered by, tumor cells demonstrating obvious piling-up.
Poorly differentiated (p/d) carcinomas show mainly solid
growth and only occasionally glandular/papillary patterns
and/or mucus production. Blood vessel and lymphatic
invasion was also explored microscopically, with
hematoxylin-eosin and elastic-fiber stained sections of
maximum tumour diameter made from paraffin-
embedded specimens.
SNP array analysis and comparisons of allelic imbalance
at the chromosome arm level and in selected
cancer-related regions
Extracted DNA was subjected to Affymetrix GeneChip
Mapping 250K arrays. Allelic imbalance was analyzed
using software termed the Copy Number Analyzer for
Affymetrix Gene Chip Mapping (CNAG Ver. 2.0) [21].
After appropriate normalization of mean array intensities,
signal ratios between tumours and anonymous normal
references were calculated in an allele-specific manner,
and allele-specific copy numbers were inferred from the
observed signal ratios based on the hidden Markov model
using the CNAG/AsCNAR software [21-23]. With this
procedure, genomic profiles of ALK fusion-positive and
-negative tumours were obtained. Datas have been depos-
ited at NCBI's Gene Expression Omnibus data repository
under GEO series accession number GSE41536.
Comparison was at two levels; a chromosome arm
level and a smaller, specific gene locus level. To do this,
first we compared average numbers of chromosome
arms altered between the two groups [24]. We called
gain or loss of each chromosomal arm when copy num-
ber change stretched more than 80% of entire length.
Secondly, we compared recurrent copy number aberra-
tions at twenty-one cancer-related loci with gains and
five with losses. These specific regions were selected
based on previous studies of the lung cancer genome
Table 1 Comparison of clinicopathological parameters in
cases with or without ALK fusion
with fusion without fusion P
n 35 95
Age (years) 58.5 62.8 0.050
gender
male 14 47 0.337
female 21 48
smoking
never 25 41 0.004
ever 10 54
pStage
I 20 60 0.532
II-IV 15 35
differentiation grade
wel 4 44 <0.001
mod+por 31 51
Predominant subtype
papillary 21 77 0.019
Acinar 13 13
Bronchioloalveolar 0 4
solid with mucin 0 1
signet 1 0
lymphatic invasion
- 24 68 0.738
+ 11 27
Vessel invasion
- 15 51 0.273
+ 20 44
TP53 mutation
- 34 75 0.014
+ 1 20
EGFR mutation
- 35 40 <0.0001
+ 0 55
KRAS mutation
- 35 88 0.189
+ 0 7
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The selected regions with relevant genes were as follows:
for gains, 1p34.3 (MYCL1), 1q21.2 (S100 family), 3q29
(MUC4), 5p15.33 (TERT), 6p21.1 (VEGF), 7p11.2 (EGFR),
7p21.1, 7q31.2 (MET), 8q24.21 (MYC), 10q11.22, 12p12.1
(KRAS), 12q14.1 (CDK4), 12q15 (MDM2), 14q13.3 (TTF1),
16p13.3, 17q12 (ERBB2), 17q25.1, 19q12 (CCNE1),
20q13.2, 20q13.32, 20q13.33 (TNFSF6B); and for losses,
9p21.3 (CDKN2A), 9p23-p24.1 (PTPRD), 10q23.31 (PTEN),
13q14 (RB1), 17p13.1 (TP53).
Statistical analysis
Clinicopathological parameters of cases with or without
ALK fusion and the frequencies of chromosome arms
changed and copy numbers of targeted loci were com-
pared by the chi-square test or the Fisher’s exact test as
appropriate. The average number of chromosome arms
altered with or without ALK fusion was compared with
Students’ t-test. Statistical significance was defined as
P=0.05 or less.
Results
Comparisons of clinicopathological profiles of tumours
with or without ALK fusion
Clinicopathological profiles of patients are summarized
in Table 1. ALK fusion-positive cases were significantly
younger and featured significantly more never-smokers
(P=0.05, P=0.004, respectively). ALK fusion-positive
tumours were histologically adenocarcinomas with not-
able characteristics such as poor differentiation as well
as an acinar type structure and mucin production, as
reported previously [7-9]. In this study, distribution of
histological subtypes differed between two groups,
namely, “acinar” subtype accounted for nearly forty per-
cent in ALK fusion positive group (Table 1). The fre-
quencies of vascular invasion, both of blood and lymph
vessels, did not significantly differ between the two groups
(P=0.738, P=0.273, respectively). In addition, the distribu-
tion of pathological stages did not vary (P=0.532).
Mutational status of TP53, EGFR and KRAS
Data for the mutational status of TP53, EGFR and KRAS
in the two groups are summarized in Table 1. Twenty-one
cases had TP53 mutations. Only one case with ALK fusion
(Case 9: 1/35, 3%) harbored a mutation, a G/A transition
at codon 273, as compared to 20 cases without ALK fusion
(20/95, 21%), the mutation rates being significantly diffe-
rent (P=0.014) (Table 1, Additional file 1: Table S2).
Twelve (12/21, 57%) of the TP53-mutated cases had a
smoking history.
EGFR and KRAS mutations were not detected among
ALK fusion-positive tumours. This fact that ALK re-
arrangement was mutually exclusive with EGFR and
KRAS mutations (P<0.0001, P=0.189, respectively) is inline with our previous studies [8]. The EGFR mutation
rate was 58% (55/95) in ALK fusion-negative cases and
decreased with the smoking burden: 70.7% (29/41) in
never smokers, 62.5% (15/24) in light smokers (0<pack-
years<20) and 36.7% in heavy smokers (more than 20
pack-years) (11/30) (Additional file 2: Figure S1). KRAS
mutations were identified in 7.4% (7/95) of ALK fusion-
negative cases, and detected only among smokers.
Though KRAS mutations were examined through
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The KRAS mutation rate increased along with the eleva-
tion of smoking index (Additional file 2: Figure S1).
These findings for EGFR and KRAS mutations are consist-
ent with previous reports from Japan, the prevalence being
quite different from that in the United States [27-29].
DNA copy number alterations of chromosome arms
We compared the allelotypes of each chromosome arm
between the two groups. Global views of chromosome
aberrations are shown in Figure 1. Note that in ALK
fusion-positive tumours, genomic copy number changes
were more evenly distributed over the chromosome
arms and high copy number gains (dark-red) in short
genomic segments were less frequently encountered
than with ALK-fusion negative examples. Significantly
different patterns of respective chromosomal arm gain
and loss were noted between the two groups. In fact, 5q,
8p, 9q, 11p and 11q were significantly more amplified,
and 6q was more deleted in ALK fusion-positive
tumours, whereas, in ALK fusion-negative tumours, 17q
was more amplified, and 8p and 9p were more deleted
(Figure 1, Table 2a, Additional file 1: Table S3-S5).
P-values for comparisons of the aberration frequency in
each chromosome arms are shown in Additional file 1:Ch 1 Ch 2
Ch 3 Ch 4 Ch 5
Ch 6 Ch 7 Ch 8
Ch 9 Ch 10 Ch 11 Ch 12
Ch 13 Ch 14 Ch 15 Ch 16 Ch 17







ALK fusion positive cases (n=35)
Figure 1 Global view of copy number alterations with or without ALK
genomic gain and its length. The color indicates the copy number of geno
beneath the chromosomes represent copy number loss: blue, 1 copy; and
of the two groups are adjusted according to the number of cases includedTable S5. When comparing global chromosome instabi-
lity levels between the two groups, average numbers of
chromosome arms with copy number gain or loss were
8.42 ±7.46 and 9.56 ±7.90 for tumours with and without
ALK fusion, respectively, as detailed in Table 3, the
difference not being statistically significant.
Chromosomal number alterations with advancement of
pathological stage
Chromosome aberration might be expected to increase
as tumours progress in stages and, if so, numbers of
chromosome arms with gain and/or loss might be larger
in advanced tumours. In fact however, when we com-
pared the number of chromosome arm altered between
pathological stage I and II-IV, total number did not in-
crease in pathological stage II-IV, though only ALK
fusion-negative tumours showing significant elevation of
chromosomal gain (Figure 2).
Comparison of gain and loss frequency of selected loci
We selected twenty-one loci with recurrent copy num-
ber gain and five loci with loss to compare small-scale
genomic aberrations. All the loci examined and P-values
are summarized in Additional file 1: Table S6, S7. In
Figure 3, stacked bar charts are shown indicating theh 1 Ch 2
h 3 Ch 4 Ch 5
h 6 Ch 7 Ch 8
h 9 Ch 10 Ch 11 Ch 12
h 13 Ch 14 Ch 15 Ch 16 Ch 17
h 18 Ch 19 Ch 20 Ch 21 Ch 22 ChX
ALK fusion negative cases (n=95)
fusion. A line above a chromosome represents one case with
mic regions: pink, 3 or 4 copies; and dark-red, ≥ 5 copies. Lines
light-green, 2 copies (homozygous deletion). Width between the lines
for ease of visual comparison.
Table 2 Comparisons of significantly altered
chromosomal arms between adenocarcinomas with and
without ALK fusion
Category Gain Loss
More frequent with ALK fusion 5q, 8p, 9q, 11p, 11q 6q
More frequent without ALK fusion 17q 8p, 9q
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copy numbers (and related genes) at 1p34.3 (MYCL1),
7p11.2 (EGFR), 7p21.1, 8q24.21 (MYC), 16p13.3, 17q12
(ERBB2) and 17q25.1 were significantly less gained, and
those at 9p21.3 (CDKN2A), 9p23-p24.1 (PTPRD), 13q14.2
(RB1) were significantly less deleted in ALK fusion-positive
tumours than fusion-negative ones, with loci related to
both oncogenes and tumour suppressor genes having fewer
changes in tumours with ALK fusion. There were no
oncogene-related loci with more gains and no suppressor
gene-related loci with more losses in tumours with ALK
fusion.
Homozygous deletions were found only at 9p21, at fre-
quencies similar between the two groups, although the
summed frequencies of heterozygous and homozygous
deletions at 9p21.3 did significantly differ. In the group
without ALK fusion, all the cases with the homozygous
deletion harbored EGFR mutations.
MYCL1, EGFR, MYC and ERBB2 are well-known onco-
genes and CDKN2A and RB1 are tumour suppressor genes
related to lung carcinogenesis. PTPRD has been suggested
to function as a tumour suppressor in several tumours, in-
cluding lung cancers [30] and brain tumours [31]. Notably,
5p15.33, including TERT (telomerase reverse transcript-
ase), had the highest rate of gain in both groups regardless
of ALK fusion (Additional file 3: Figure S2 and Additional
file 1: Table S7).
Taken together, ALK fusion-positive tumours showed
similar levels of overall chromosome instability, but when
focusing on particular cancer-related regions, significantly
fewer copy number gains at oncogene-related loci and sig-
nificantly fewer deletions at suppressor gene-related loci.
Discussion
Recurrent chromosome translocation has been accepted to
play an important role in the pathogenesis of hematological
malignancies, but not of solid tumours. Recently, however,Table 3 Comparisons of numbers of chromosome arms
with aberrations between adenocarcinomas with or
without ALK fusion
with ALK fusion (n=35) without ALK fusion (n=95) P
Gains 5.97±6.75 6.21±6.95 0.859
Losses 2.46±3.06 3.35±4.34 0.196
Total 8.42±7.46 9.56±7.90 0.454
Note that significant differences are not detected.chromosome rearrangements in solid tumours such as pros-
tate cancer and non-small cell lung cancer have been
reported [32]. ALK fusion was originally described in anaplas-
tic large-cell lymphoma as a chimeric protein NPM-ALK
resulting from a translocation. More recently, evidence
has accumulated that the EML4-ALK fusion gene
defines a novel subclass of lung adenocarcinomas with
distinct clinicopathological features [7-9], so that it has
emerged as a target for therapy. We focused here for the
first time on allelic imbalance of tumours with ALK fu-
sion with a novel technique which has already shown
the involvement of loss of A20 function in the patho-
genesis of a subset of B-cell lymphomas [33] and gain of
function of C-CBL tumour suppressor in myeloid neo-
plasms [34]. Applying this methodology, we demon-
strated that lung adenocarcnomas with ALK fusion
feature less amplification of loci with oncogenes and
fewer deletions of loci related to tumour suppressor
genes, although global chromosome aberrations were
similar between tumours with and without ALK fusion.
suggesting that the fusion gene is a driver mutation, not
just a passenger mutation.
Genetic instability was here categorized into two
groups for simplicity, at the chromosomal level and at
the nucleotide level. We earlier found the former to play
a more important role in lung carcinogenesis, the fre-
quency of LOH (loss of heterozygosity) being higher in
less-differentiated tumours [35]. ALK fusion positive
tumours are more common among non-smokers and
the younger population, similar to those with EGFR
mutations. We had expected fewer chromosome aberra-
tions in ALK fusion-positive tumours because tumours
arising in such people usually harbor less LOH and a
lower TP53 mutation rate than smokers [36-38]. Con-
trary to our expectation, the global copy number
changes at the chromosomal arm level did not differ be-
tween the two groups, although significant differences of
alteration frequency at the individual chromosomal arms
were seen. In addition, only ALK fusion-negative tumours
showed an increase of the frequency of chromosome arm
gain with the advancement of disease stage. Furthermore,
at the smaller-genomic scale level, ALK fusion-positive
tumours were less amplified at the loci containing EGFR
family genes, 7p11.2 (EGFR), 17q12 (ERBB2) and other
loci, 1p34.3 (MYCL), 7p21.1, 8q24.21 (MYC), 16p13.3 and
17q25.1. EGFR and ERBB2 play important roles by dimer-
izing when their ligands binds to produce downward
growth signals to the tumour cells. Mutations and activa-
tion of these genes may drive carcinogenesis [39], and
increased expression is associated with a poor prognosis
in NSCLCs [40-43]. ALK fusion positive tumours are
speculated to be less dependent on the actions of onco-
genes and tumour-suppressor genes induced by copy
number changes. Our results may also indicate that there
p Stage with ALK fusion P without ALK fusion P
I 5.05 6.07 4.97 6.41
Gain n.s. 0.017
II IV 7.20 7.59 8.53 7.43
I 1.90 3.11 3.60 4.66
Loss n.s. n.s.
II IV 3.20 2.93 2.88 3.80
I 6.95 6.78 8.57 7.71
Gain +Loss n.s. n.s.
II IV 10.4 8.09 11.41 8.11
Figure 2 Comparisons of numbers of chromosome arms altered with or without ALK fusion in different pathological stages. Note that,
whereas tumours in higher stages show more gains than stage I tumours when the tumours have no ALK fusion, ALK fusion positive tumours
exhibit no such difference. p-Stage; pathological stage, n.s.; not statistically significant.
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adenocarcinomas independent of ALK fusion, such as the
5p15.33 region, including TERT.
As for genomic loss, 9p21.3 (CDKN2A), 9p23-p24.1
(PTPRD) and 13q14.2 (RB1) were significantly less fre-
quently deleted in ALK fusion-positive tumours. Homo-
zygous deletion was seen only at 9p21.3 including
CDKN2A and limited to EGFR-mutated tumours among
ALK fusion-negative neoplasms as reported in the lit-
erature [44] and also seen in ALK-fusion positive ones.
That deletion of 9p23-24.1 and 13q14.2 including
tumour suppressor genes was rare in ALK fusion-
positive tumours suggests that they can grow even if the
functions of these suppressor genes are retained.
Of all the selected loci, 5p15.33 containing TERT
(telomerase reverse transcriptase isoform 2) showed
the highest frequency of recurring gain regardless of
ALK fusion. The enzyme is important for telomere re-
generation and maintenance resulting in a growth ad-
vantage and Zhang et al. reported that the locus is afrequent target of amplification during tumourigenesis [45].
Copy number gain of this locus significantly correlates with
telomerase activity [46] and is one of the most consist-
ent alterations in the early stages of non-small cell lung
cancer [47]. In addition, increased susceptibility to lung
cancer development associated with a SNP polymorphism
of this locus has been reported [48,49]. The fact that most
human tumour cells have telomerase activity indicates
that its acquisition is vital for carcinogenesis and cell
immortalization, and it might explain the reason why lung
adenocarcinomas with or without ALK fusion shows simi-
lar frequency of copy number gain of this locus.
Our results have some therapeutic relevance. The fact
that there are less involvement of other oncogenes and
tumor suppressor genes may be related to dramatic
responses to targeted drugs because of intact cellular
processes including apoptosis pathways. In this regard,
there is an interesting paper by Camidge et al. [50],
demonstrating the inverse relationship between fused
and isolated red copy number on FISH might suggest
Figure 3 Significant differences in copy number change detected at seven loci for gain and three loci for loss among twenty-six
selected loci. Colors of the stacked bars represent copy number: orange, 3,4 copies; red, ≥ 5 copies; blue, 1 copy loss (heterozygous deletion),
light green: 2 copy losses (homozygous deletion). 17q12, 17q25.1 show remarkable differences in copy number gain between ALK fusion-positive
and -negative tumours.
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type of non-small cell lung cancer. Comparing closely,
however, between their and our results, our study clearly
revealed the overall frequency of chromosome aberra-
tions are similar between ALK fusion positive and nega-
tive tumors, suggesting not “near-diploid”. But, certainly,
we need more investigations on genomic instability of
ALK fusion positive tumors.
It is well known that smoking causes genomic changes
with allelic imbalance [20]. As shown in Table 1, smo-
kers dominate never smokers in the group without fu-
sion whereas the fusion-positive group has more never
smokers than smokers. Since the tumors without ALK
fusion include EGFR-mutated tumors, most of which are
from never smokers, the ALK fusion-negative group is
certainly heterogeneous. In due course, a study that
describes comparisons of allelotypes of non-smoker’s
tumors between with ALK fusion and with EGFR muta-
tion should be warranted.Conclusions
Although overall frequencies of aberrations at the
chromosome arm level do not appear to significantly dif-
fer between ALK fusion-positive and -negative tumors,
smaller genomic regions including cancer-related genes
do show significant variation. Thus tumors with ALK
fusion feature significantly fewer copy number gains
and losses at loci containing oncogenes and tumor-
suppressor genes, respectively. This implies that ALK
fusion itself exerts very strong driving forces for
tumorigenesis, in other words, that ALK fusion is a driver
mutation, not just a passenger mutation.Additional files
Additional file 1: Table S1. Frequencies of fusion variants of ALK
rearrangements. Table S2. Cases with TP53 mutations and their smoking
status. Table S3. Chromosomal arms and number of cases with gain
with or without ALK fusion. Table S4. Chromosomal arms and number
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http://www.biomedcentral.com/1471-2407/13/8of cases with loss with or without ALK fusion. Table S5. P-values for
comparisons of the frequencies of chromosome aberrations in all
chromosome arms between tumours with or without ALK fusion. Table
S6. Number of cases with copy number gain or loss at selected loci with
or without ALK fusion. Table S7. Significance of the differences in
frequencies of copy number changes (gains and losses) between
tumours with or without ALK fusion.
Addtional file 2: Figure S1. Mutation rates for EGFR, TP53 and KRAS
according to cumulative smoking are shown. EGFR and KRAS mutations
were only detected among ALK fusion negative cases, so ALK fusion
positive cases were not included in the analysis. Note the gradually
decrease in EGFR mutation rate with increase in cumulative smoking.
KRAS mutations were detected only among smokers.
Additional file 3: Figure S2. Comparisons of copy number alteration
rates at selected loci with or without ALK fusion. Note that 5p15.33
including TERT shows the highest gain both in ALK fusion positive and
negative tumours, the frequencies being identical.
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